US Patent Number
10,344,095
Publication Date
7-9-2019
Abstract
Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis.
Assignees
University of Kentucky Research Foundation, Lexington, KY (US)
Application Number
11/357,288
Filing Date
02/16/2006
Recommended Citation
Ambati, Jayakrishna, "CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration" (2019). Ophthalmology and Visual Science Faculty Patents. 24.
https://uknowledge.uky.edu/ophthalmology_patents/24
